Joakim Dillner

Joakim Dillner's AcademicInfluence.com Rankings

Joakim Dillner

Biology

#6504

World Rank

#9235

Historical Rank

Biotechnology

#59

World Rank

#60

Historical Rank

Genetics

#604

World Rank

#686

Historical Rank

Molecular Biology

#671

World Rank

#688

Historical Rank

biology Degrees

Download Badge

Biology

Why Is Joakim Dillner Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Joakim Dillner's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions (2007) (1755)
Efficacy of HPV-based screening for prevention of invasive cervical cancer: follow-up of four European randomised controlled trials (2014) (1236)
Human papillomavirus and Papanicolaou tests to screen for cervical cancer. (2007) (656)
Overview of human papillomavirus-based and other novel options for cervical cancer screening in developed and developing countries. (2008) (644)
Long term predictive values of cytology and human papillomavirus testing in cervical cancer screening: joint European cohort study (2008) (637)
Safety and immunogenicity trial in adult volunteers of a human papillomavirus 16 L1 virus-like particle vaccine. (2001) (620)
Guidelines for human papillomavirus DNA test requirements for primary cervical cancer screening in women 30 years and older (2009) (578)
Chapter 9: Clinical applications of HPV testing: a summary of meta-analyses. (2006) (548)
Impact of human papillomavirus (HPV)-6/11/16/18 vaccine on all HPV-associated genital diseases in young women. (2010) (533)
Type-specific persistence of human papillomavirus DNA before the development of invasive cervical cancer. (1999) (516)
The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in sexually active women aged 16-26 years. (2009) (509)
HPV Vaccination and the Risk of Invasive Cervical Cancer. (2020) (459)
The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in generally HPV-naive women aged 16-26 years. (2009) (451)
Both high and low levels of blood vitamin D are associated with a higher prostate cancer risk: A longitudinal, nested case‐control study in the Nordic countries (2004) (440)
Serotypes of Chlamydia trachomatis and risk for development of cervical squamous cell carcinoma. (2001) (419)
Human papillomavirus infection as a risk factor for squamous-cell carcinoma of the head and neck. (2001) (394)
Should donors be allowed to give broad consent to future biobank research? (2006) (385)
Screening-preventable cervical cancer risks: evidence from a nationwide audit in Sweden. (2008) (367)
Four year efficacy of prophylactic human papillomavirus quadrivalent vaccine against low grade cervical, vulvar, and vaginal intraepithelial neoplasia and anogenital warts: randomised controlled trial (2010) (341)
Smoking, diet, pregnancy and oral contraceptive use as risk factors for cervical intra-epithelial neoplasia in relation to human papillomavirus infection (2000) (332)
Strategies for global control of cervical cancer (1995) (327)
Virologic versus cytologic triage of women with equivocal Pap smears: a meta-analysis of the accuracy to detect high-grade intraepithelial neoplasia. (2004) (323)
A Pooled Analysis of Continued Prophylactic Efficacy of Quadrivalent Human Papillomavirus (Types 6/11/16/18) Vaccine against High-grade Cervical and External Genital Lesions (2009) (321)
Penile cancer: epidemiology, pathogenesis and prevention (2009) (311)
An altered immune response to Epstein-Barr virus in multiple sclerosis (2004) (306)
Chlamydia trachomatis infection as a risk factor for invasive cervical cancer (2000) (302)
Etiology of Squamous Cell Carcinoma of the Penis (2000) (296)
A systematic review of the prevalence of mucosal and cutaneous human papillomavirus types. (2013) (269)
Surface conformational and linear epitopes on HPV-16 and HPV-18 L1 virus-like particles as defined by monoclonal antibodies. (1996) (265)
Efficacy of HPV DNA testing with cytology triage and/or repeat HPV DNA testing in primary cervical cancer screening. (2009) (250)
The serological response to papillomaviruses. (1999) (231)
International standardization and classification of human papillomavirus types. (2015) (231)
Clinical utility of HPV-DNA detection: triage of minor cervical lesions, follow-up of women treated for high-grade CIN: an update of pooled evidence. (2005) (227)
Cervical carcinoma and reproductive factors: Collaborative reanalysis of individual data on 16,563 women with cervical carcinoma and 33,542 women without cervical carcinoma from 25 epidemiological studies (2006) (217)
Evaluation of quadrivalent HPV 6/11/16/18 vaccine efficacy against cervical and anogenital disease in subjects with serological evidence of prior vaccine type HPV infection (2009) (215)
A population‐based prospective study of Chlamydia trachomatis infection and cervical carcinoma (2002) (195)
Screening and cervical cancer cure: population based cohort study (2012) (193)
High levels of circulating testosterone are not associated with increased prostate cancer risk: A pooled prospective study (2004) (191)
European guidelines for quality assurance in cervical cancer screening. Summary of the supplements on HPV screening and vaccination (2015) (191)
HPV antibody levels and clinical efficacy following administration of a prophylactic quadrivalent HPV vaccine. (2008) (190)
Smoking as a major risk factor for cervical cancer and pre‐cancer: Results from the EPIC cohort (2014) (187)
Are 20 human papillomavirus types causing cervical cancer? (2014) (186)
Chlamydia trachomatis infection and persistence of human papillomavirus (2005) (179)
Cutaneous human papillomaviruses found in sun-exposed skin: Beta-papillomavirus species 2 predominates in squamous cell carcinoma. (2007) (175)
Seropositivities to human papillomavirus types 16, 18, or 33 capsids and to Chlamydia trachomatis are markers of sexual behavior. (1996) (173)
Monoclonal and polyclonal antibodies against Epstein-Barr virus nuclear antigen 5 (EBNA-5) detect multiple protein species in Burkitt's lymphoma and lymphoblastoid cell lines (1987) (170)
Serologically diagnosed infection with human papillomavirus type 16 and risk for subsequent development of cervical carcinoma: nested case-control study (1996) (164)
Epidemiology of Human Papillomavirus Infection (2000) (160)
High prevalence of cutaneous human papillomavirus DNA on the top of skin tumors but not in "Stripped" biopsies from the same tumors. (2004) (156)
Status of implementation and organization of cancer screening in The European Union Member States—Summary results from the second European screening report (2018) (155)
HPV-FASTER: broadening the scope for prevention of HPV-related cancer (2016) (153)
Modified General Primer PCR System for Sensitive Detection of Multiple Types of Oncogenic Human Papillomavirus (2009) (152)
Stability over time of serum antibody levels to human papillomavirus type 16. (1998) (151)
Seroepidemiology of the human polyomaviruses. (2003) (144)
Prospective seroepidemiologic study of human papillomavirus infection as a risk factor for invasive cervical cancer. (1997) (140)
Quadrivalent Human Papillomavirus Vaccine Effectiveness: A Swedish National Cohort Study (2013) (136)
Cervical cancer screening in Europe: Quality assurance and organisation of programmes. (2015) (128)
Immune responses against human papillomavirus (HPV) type 16 virus-like particles in a cohort study of women with cervical intraepithelial neoplasia. II. Systemic but not local IgA responses correlate with clearance of HPV-16. (1999) (121)
Human papillomavirus infection as a risk factor for anal and perianal skin cancer in a prospective study (2002) (118)
Global Proficiency Study of Human Papillomavirus Genotyping (2010) (118)
Long term duration of protective effect for HPV negative women: follow-up of primary HPV screening randomised controlled trial (2014) (116)
ICTV Virus Taxonomy Profile: Papillomaviridae (2018) (116)
The Epstein-Barr virus proteins. (1988) (113)
Conization for cervical intraepithelial neoplasia is followed by disappearance of human papillomavirus deoxyribonucleic acid and a decline in serum and cervical mucus antibodies against human papillomavirus antigens. (1996) (112)
Triage of women with equivocal or low-grade cervical cytology results: a meta-analysis of the HPV test positivity rate (2009) (112)
Immunity to oncogenic human papillomaviruses. (2001) (111)
Vaccination protects against invasive HPV‐associated cancers (2018) (111)
Nordic biological specimen banks as basis for studies of cancer causes and control – more than 2 million sample donors, 25 million person years and 100 000 prospective cancers (2007) (110)
Time trends in incidence and prevalence of human papillomavirus type 6, 11 and 16 infections in Finland. (2003) (110)
Cervical Carcinoma and Sexual Behavior: Collaborative Reanalysis of Individual Data on 15,461 Women with Cervical Carcinoma and 29,164 Women without Cervical Carcinoma from 21 Epidemiological Studies (2009) (107)
Circulating enterolactone and prostate cancer risk: A Nordic nested case‐control study (2002) (104)
Epigenome-based cancer risk prediction: rationale, opportunities and challenges (2018) (104)
Viral Load of Human Herpesvirus 8 in Peripheral Blood of Human Immunodeficiency Virus-Infected Patients with Kaposi's Sarcoma (2001) (102)
Comparison of Development of Serum Antibodies to HPV16 and HPV33 and Acquisition of Cervical HPV DNA Among Sexually Experienced and Virginal Young Girls: A Longitudinal Cohort Study (1996) (102)
A population-based five-year follow-up study of cervical human papillomavirus infection. (2000) (102)
Nucleic acid tests for the detection of alpha human papillomaviruses. (2012) (101)
Herpes simplex virus and risk of cervical cancer: a longitudinal, nested case-control study in the nordic countries. (2002) (101)
The Influence of Hormonal Factors on the Risk of Developing Cervical Cancer and Pre-Cancer: Results from the EPIC Cohort (2016) (101)
Sero‐epidemiologal association between human‐papillomavirus infection and risk of prostate cancer (1998) (101)
A monoclonal antibody against intact human papillomavirus type 16 capsids blocks the serological reactivity of most human sera. (1997) (100)
Is smoking an independent risk factor for invasive cervical cancer? A nested case-control study within Nordic biobanks. (2008) (100)
Sexual behaviour and papillomavirus exposure in cervical intraepithelial neoplasia: a population-based case-control study. (1999) (100)
Cervical cancer screening in Sweden. (2000) (99)
Review of current knowledge on HPV vaccination: an appendix to the European Guidelines for Quality Assurance in Cervical Cancer Screening. (2007) (98)
Maternal herpesvirus infections and risk of acute lymphoblastic leukemia in the offspring. (2003) (98)
Performance of colorectal cancer screening in the European Union Member States: data from the second European screening report (2018) (98)
A population-based seroepidemiological study of cervical cancer. (1994) (97)
Mapping of linear epitopes of human papillomavirus type 16: The E1, E2, E4, E5, E6 and E7 open reading frames (1990) (97)
Strategies for the introduction of human papillomavirus vaccination: modelling the optimum age- and sex-specific pattern of vaccination in Finland (2007) (96)
Association of varying number of doses of quadrivalent human papillomavirus vaccine with incidence of condyloma. (2014) (96)
Prospective seroepidemiological evidence that human papillomavirus type 16 infection is a risk factor for oesophageal squamous cell carcinoma (1995) (96)
Different HLA‐DR‐DO haplotypes are associated with cervical intraepithelial neoplasia among human papillomavirus type‐16 seropositive and seronegative Swedish women (1996) (95)
Antibodies against a synthetic peptide identify the Epstein-Barr virus-determined nuclear antigen. (1984) (94)
Reliable high risk HPV DNA testing by polymerase chain reaction: an intermethod and intramethod comparison. (1999) (93)
HPV type-specific risks of high-grade CIN during 4 years of follow-up: A population-based prospective study (2007) (93)
Chlamydia trachomatis infection and risk of cervical intraepithelial neoplasia (2011) (92)
Four virally determined nuclear antigens are expressed in Epstein-Barr virus-transformed cells. (1986) (92)
A 12-Year Follow-up on the Long-Term Effectiveness of the Quadrivalent Human Papillomavirus Vaccine in 4 Nordic Countries (2018) (90)
Deep sequencing extends the diversity of human papillomaviruses in human skin (2014) (90)
Rate of Human Papillomavirus Clearance After Treatment of Cervical Intraepithelial Neoplasia (2002) (89)
Ethical framework for previously collected biobank samples (2007) (88)
Cutaneous human papillomaviruses persist on healthy skin. (2007) (88)
Epidemiologic approaches to evaluating the potential for human papillomavirus type replacement postvaccination. (2013) (88)
No excess risk of cervical carcinoma among women seropositive for both HPV16 and HPV6/11 (1999) (88)
Population‐based type‐specific prevalence of high‐risk human papillomavirus infection in middle‐aged Swedish Women (2002) (86)
Prostate cancer risk and serologic evidence of human papilloma virus infection: a population-based case-control study. (2003) (86)
Clinical trials of human papillomavirus vaccines and beyond (2015) (86)
Prospective Seroepidemiologic Study of Human Papillomavirus and Other Risk Factors in Cervical Cancer (2011) (85)
An Epstein-Barr virus (EBV)-determined nuclear antigen (EBNA5) partly encoded by the transformation-associated Bam WYH region of EBV DNA: preferential expression in lymphoblastoid cell lines. (1986) (85)
Efficacy of RG1-VLP Vaccination against Infections with Genital and Cutaneous Human Papillomaviruses (2013) (85)
High throughput sequencing reveals diversity of Human Papillomaviruses in cutaneous lesions (2011) (84)
A prospective, seroepidemiological study of the role of human papillomavirus in esophageal cancer in Norway. (1997) (84)
Prospective seroepidemiological study of role of human papillomavirus in non-cervical anogenital cancers (1997) (82)
Seroreactivity to Cutaneous Human Papillomaviruses among Patients with Nonmelanoma Skin Cancer or Benign Skin Lesions (2008) (82)
Clinical trials of human papillomavirus vaccines and beyond (2013) (81)
Evaluation of the Long-Term Anti-Human Papillomavirus 6 (HPV6), 11, 16, and 18 Immune Responses Generated by the Quadrivalent HPV Vaccine (2015) (81)
Virologic versus cytologic triage of women with equivocal Pap smears: A meta-analysis of the accuracy to detect high-grade intraepithelial neoplasia (2004) (81)
Human papillomavirus infection and esophageal cancer: a nationwide seroepidemiologic case-control study in Sweden. (1999) (81)
Antibodies against linear and conformational epitopes of human papillomavirus type 16 that independently associate with incident cervical cancer (2006) (81)
A synthetic peptide defines a serologic IgA response to a human papillomavirus-encoded nuclear antigen expressed in virus-carrying cervical neoplasia. (1989) (80)
Recurrent Respiratory Papillomatosis: HPV Genotypes and Risk of High-Grade Laryngeal Neoplasia (2014) (78)
Global Improvement in Genotyping of Human Papillomavirus DNA: the 2011 HPV LabNet International Proficiency Study (2013) (78)
Identification of human papillomavirus seroconversions. (1995) (76)
Colposcopic and histopathologic evaluation of women participating in population-based screening for human papillomavirus deoxyribonucleic acid persistence. (2005) (75)
Seroprevalence of human papillomaviruses and Chlamydia trachomatis and cervical cancer risk: nested case-control study. (2007) (74)
Evaluation of antibody response to human papillomavirus early proteins in women in whom cervical cancer developed 1 to 20 years later. (2003) (73)
The 2010 Global Proficiency Study of Human Papillomavirus Genotyping in Vaccinology (2012) (73)
2020 List of human papillomavirus assays Suitable for primary cervical cancer screening. (2021) (71)
A report on the current status of European research on the use of human papillomavirus testing for primary cervical cancer screening (2006) (71)
Serological evidence for protection by human papillomavirus (HPV) type 6 infection against HPV type 16 cervical carcinogenesis. (1999) (71)
A survey of seroprevalence of human papillomavirus types 16, 18 and 33 among children (1999) (70)
Translational Mini‐Review Series on Vaccines: Monitoring of human papillomavirus vaccination (2007) (70)
Mapping of linear epitopes of human papillomavirus type 16: The L1 and L2 open reading frames (1990) (70)
Combined effect of smoking and human papillomavirus type 16 infection in cervical carcinogenesis. (1998) (69)
Prospective study of human papillomavirus and risk of cervical adenocarcinoma (2010) (69)
Results of the first WHO international collaborative study on the standardization of the detection of antibodies to human papillomaviruses (2006) (69)
ViraMiner: Deep learning on raw DNA sequences for identifying viral genomes in human samples (2019) (69)
Metagenomic sequencing of "HPV-negative" condylomas detects novel putative HPV types. (2013) (68)
Cancer risks after solid organ transplantation and after long‐term dialysis (2017) (68)
Chapter 28: Studies to assess the long-term efficacy and effectiveness of HPV vaccination in developed and developing countries. (2006) (68)
Prospective Study of Human Papillomavirus (HPV) Types, HPV Persistence, and Risk of Squamous Cell Carcinoma of the Cervix (2010) (67)
Smoking impairs human papillomavirus (HPV) type 16 and 18 capsids antibody response following natural HPV infection (2008) (66)
Serum antibodies against p53 in relation to cancer risk and prognosis in breast cancer: a population-based epidemiological study (1999) (66)
Ten-year follow-up of human papillomavirus vaccine efficacy against the most stringent cervical neoplasia end-point—registry-based follow-up of three cohorts from randomized trials (2017) (66)
Assessing quality and functionality of DNA from fresh and archival dried blood spots and recommendations for quality control guidelines. (2007) (66)
Interaction of Factors Related to the Metabolic Syndrome and Vitamin D on Risk of Prostate Cancer (2007) (65)
Comparison of use of vaginal HPV self-sampling and offering flexible appointments as strategies to reach long-term non-attending women in organized cervical screening. (2013) (65)
Sero-epidemiological association between human-papillomavirus infection and risk of prostate cancer. (1998) (64)
Final analysis of a 14-year long-term follow-up study of the effectiveness and immunogenicity of the quadrivalent human papillomavirus vaccine in women from four nordic countries (2020) (64)
Monitoring of human papillomavirus vaccination (2011) (64)
Reactivity to human papillomavirus type 16 L1 virus-like particles in sera from patients with genital cancer and patients with carcinomas at five different extragenital sites (2003) (64)
A prospective study on the risk of cervical intra‐epithelial neoplasia among healthy subjects with serum antibodies to HPV compared with HPV DNA in cervical smears (1996) (63)
Characterization of humoral immune responses against p16, p53, HPV16 E6 and HPV16 E7 in patients with HPV‐associated cancers (2008) (63)
Unbiased Approach for Virus Detection in Skin Lesions (2013) (62)
Dietary factors and in situ and invasive cervical cancer risk in the European prospective investigation into cancer and nutrition study (2011) (62)
BamHI E region of the Epstein-Barr virus genome encodes three transformation-associated nuclear proteins. (1988) (62)
JC viral loads in patients with Crohn’s disease treated with immunosuppression: can we screen for elevated risk of progressive multifocal leukoencephalopathy? (2008) (61)
Cohort Profile: The Janus Serum Bank Cohort in Norway. (2016) (61)
Association of serum immunoglobulin G antibodies against human papillomavirus type 16 capsids with anal epidermoid carcinoma. (1995) (60)
In Vivo and In Vitro Intragenomic Rearrangement of TT Viruses (2007) (60)
Change in Population Prevalences of Human Papillomavirus after Initiation of Vaccination: The High-Throughput HPV Monitoring Study (2014) (60)
Staphylococcus aureus and Squamous Cell Carcinoma of the Skin (2009) (59)
Type specificity and significance of different isotypes of serum antibodies to human papillomavirus capsids. (2000) (59)
Human Papillomavirus 16, 18, and 33 Infections and Risk of Prostate Cancer: A Nordic Nested Case-Control Study (2005) (59)
Use of human papillomavirus DNA testing to compare equivocal cervical cytologic interpretations in the United States, Scandinavia, and the United Kingdom (2002) (59)
Long‐term HPV type‐specific risks of high‐grade cervical intraepithelial lesions: A 14‐year follow‐up of a randomized primary HPV screening trial (2015) (58)
Heparan sulfate proteoglycans interact exclusively with conformationally intact HPV L1 assemblies: Basis for a virus‐like particle ELISA (2005) (57)
Chapter 23: International Standard reagents for harmonization of HPV serology and DNA assays--an update. (2006) (57)
Comparison between the Hybrid Capture II Test and a PCR-Based Human Papillomavirus Detection Method for Diagnosis and Posttreatment Follow-Up of Cervical Intraepithelial Neoplasia (2005) (57)
Cervical mucus antibodies against human papillomavirus type 16, 18, and 33 capsids in relation to presence of viral DNA (1996) (56)
Correlates of the spread of human papillomavirus infection. (2000) (56)
Human papillomavirus infection, risk for subsequent development of cervical neoplasia and associated population attributable fraction. (2001) (56)
Four novel human betapapillomaviruses of species 2 preferentially found in actinic keratosis. (2008) (55)
Alcohol, smoking and human papillomavirus in laryngeal carcinoma: a Nordic prospective multicenter study (2007) (55)
Cancer Prevention Europe (2019) (55)
Prospective study of human papillomavirus seropositivity and risk of nonmelanoma skin cancer. (2012) (55)
SARS-CoV-2 RNA in serum as predictor of severe outcome in COVID-19: a retrospective cohort study. (2020) (54)
High-risk human papillomavirus status and prognosis in invasive cervical cancer: A nationwide cohort study (2018) (54)
Human papillomavirus type 197 is commonly present in skin tumors (2015) (54)
Human papillomavirus type 16 capsids expose multiple type-restricted and type-common antigenic epitopes. (1995) (54)
Evaluation of enzyme-linked immunosorbent assays with two synthetic peptides of Epstein-Barr virus for diagnosis of infectious mononucleosis. (1990) (54)
Human papillomavirus type‐specific persistence and recurrence after treatment for cervical dysplasia (2014) (53)
A population-based cohort study of KIR genes and genotypes in relation to cervical intraepithelial neoplasia. (2005) (53)
Antibodies to Merkel cell polyomavirus correlate to presence of viral DNA in the skin. (2011) (52)
High-throughput genotyping of oncogenic human papilloma viruses with MALDI-TOF mass spectrometry. (2008) (52)
Molecular methods for identification and characterization of novel papillomaviruses. (2015) (52)
Malignant epithelial tumors (2004) (51)
Immunogenicity of HPV prophylactic vaccines: Serology assays and their use in HPV vaccine evaluation and development (2018) (51)
Cervical screening: ESGO-EFC position paper of the European Society of Gynaecologic Oncology (ESGO) and the European Federation of Colposcopy (EFC) (2020) (51)
Genetic predisposition, parity, age at first childbirth and risk for breast cancer (2012) (51)
Next generation sequencing for human papillomavirus genotyping. (2013) (50)
Seropositivity against HPV 16 capsids: a better marker of past sexual behaviour than presence of HPV DNA. (1997) (50)
Gender‐neutral vaccination provides improved control of human papillomavirus types 18/31/33/35 through herd immunity: Results of a community randomized trial (III) (2018) (50)
Trends in seroprevalence of human papillomavirus type 16 among pregnant women in Stockholm, Sweden, during 1969–1989 (1998) (50)
Characterization of a second Epstein‐Barr virus‐determined nuclear antigen associated with the BamHI WYH region of EBV DNA (1985) (49)
Tumor necrosis factor a-11 and DR15-DQ6 (B*0602) haplotype increase the risk for cervical intraepithelial neoplasia in human papillomavirus 16 seropositive women in Northern Sweden. (2000) (49)
Antigenic and immunogenic epitopes shared by human papillomavirus type 16 and bovine, canine, and avian papillomaviruses (1991) (49)
High risk genital papillomavirus infections are not spread vertically (1999) (49)
Primary screening for human papillomavirus compared with cytology screening for cervical cancer in European settings: cost effectiveness analysis based on a Dutch microsimulation model (2012) (49)
A Novel and Rapid PCR-Based Method for Genotyping Human Papillomaviruses in Clinical Samples (2000) (47)
Human Papillomavirus Vaccination of Boys and Extended Catch-up Vaccination: Effects on the Resilience of Programs. (2016) (47)
Serum and salivary IgA antibodies against a defined epitope of the Epstein‐Barr virus nuclear antigen (EBNA) are elevated in nasopharyngeal carcinoma (1990) (47)
Prospective seroepidemiologic study on the role of Human Papillomavirus and other infections in cervical carcinogenesis: Evidence from the EPIC cohort (2014) (47)
Evaluation of antibodies to human papillomavirus as prognostic markers in cervical cancer patients. (2002) (47)
Lymphoblastoid cell lines and burkitt‐lymphoma‐derivee cell lines differ in the expression of a second epstein‐barr virus encoded nuclear antigen (1986) (47)
Towards quality and order in human papillomavirus research. (2018) (47)
Risk of invasive cervical cancer after atypical glandular cells in cervical screening: nationwide cohort study (2016) (46)
Comparison of archival plasma and formalin-fixed paraffin-embedded tissue for genotyping in hepatocellular carcinoma. (2005) (46)
Human papillomavirus type 16 capsid proteins produced from recombinant Semliki Forest virus assemble into virus-like particles. (1995) (46)
Three novel papillomaviruses (HPV109, HPV112 and HPV114) and their presence in cutaneous and mucosal samples. (2010) (45)
EUROGIN 2008 roadmap on cervical cancer prevention (2009) (45)
Impact of gender‐neutral or girls‐only vaccination against human papillomavirus—Results of a community‐randomized clinical trial (I) (2018) (44)
Endogenous steroid hormone levels in early pregnancy and risk of testicular cancer in the offspring: A nested case–referent study (2009) (44)
Joint effects of different human papillomaviruses and Chlamydia trachomatis infections on risk of squamous cell carcinoma of the cervix uteri. (2004) (44)
Regular disappearance of the human papillomavirus genome after conization of cervical dysplasia by carbon dioxide laser. (2000) (44)
Infrastructure and Facilities for Human Biobanking in Low- and Middle-Income Countries: A Situation Analysis (2015) (44)
Antibodies against synthetic peptides react with the second Epstein‐Barr virus‐associated nuclear antigen. (1985) (43)
Prevalence and stability of human serum antibodies to simian virus 40 VP1 virus-like particles. (2005) (43)
Serological diagnosis of human polyomavirus infection. (2006) (43)
A randomized trial of basing treatment on human papillomavirus and/or cytology results in low-grade cervical lesion triage. (2008) (43)
Serum antibody response to the heat shock protein 60 of Chlamydia trachomatis in women with developing cervical cancer. (2003) (43)
Multiplex Detection of Human Herpesviruses from Archival Specimens by Using Matrix-Assisted Laser Desorption Ionization-Time of Flight Mass Spectrometry (2007) (43)
Primary human papillomavirus testing in organized cervical screening (2013) (42)
The Participation of HPV-Vaccinated Women in a National Cervical Screening Program: Population-Based Cohort Study (2015) (42)
Tumor necrosis factor A and MHC class I chain related gene A (MIC-A) polymorphisms in Swedish patients with cervical cancer. (2001) (42)
European Code against Cancer 4th Edition: Infections and Cancer. (2015) (42)
Management of women with human papillomavirus persistence: long‐term follow‐up of a randomized clinical trial (2017) (42)
Targeting Human Papillomavirus to Reduce the Burden of Cervical, Vulvar and Vaginal Cancer and Pre-Invasive Neoplasia: Establishing the Baseline for Surveillance (2014) (42)
A candidate CpG SNP approach identifies a breast cancer associated ESR1‐SNP (2011) (41)
Seropositivity to human herpesvirus 8 in relation to sexual history and risk of sexually transmitted infections among women (2000) (41)
Translational Cancer Research: Balancing Prevention and Treatment to Combat Cancer Globally (2014) (40)
Identification of a cytotoxic T-lymphocyte epitope in the human papillomavirus type 16 E2 protein. (1997) (40)
Subtype HPV38b[FA125] demonstrates heterogeneity of human papillomavirus type 38 (2006) (40)
No excess risk for colorectal cancer among subjects seropositive for the JC polyomavirus (2007) (40)
Combined effect of low-penetrant SNPs on breast cancer risk (2011) (40)
Neutralisation sensitivity of the SARS-CoV-2 omicron (B.1.1.529) variant: a cross-sectional study (2022) (40)
Endogenous Sex Steroids and Risk of Cervical Carcinoma: Results from the EPIC Study (2011) (40)
Human papillomavirus genotypes in cervical cancers in Mozambique. (2004) (39)
Randomised health services studies (2012) (38)
Human Papillomavirus neutralizing and cross-reactive antibodies induced in HIV-positive subjects after vaccination with quadrivalent and bivalent HPV vaccines. (2016) (38)
Methylation in Predicting Progression of Untreated High-grade Cervical Intraepithelial Neoplasia (2019) (38)
Genetic polymorphism of chemokine receptors CCR2 and CCR5 in Swedish cervical cancer patients. (2006) (38)
Chlamydial Antibodies and Risk of Prostate Cancer (2005) (38)
A prospective study of the relationship between prediagnostic Human Papillomavirus seropositivity and HPV DNA in subsequent cervical carcinomas (2002) (37)
Machine Learning for detection of viral sequences in human metagenomic datasets (2018) (37)
Risk of invasive cervical cancer associated with polymorphic HLA DR/DQ haplotypes (2002) (37)
No evidence of enteroviruses in the intestine of patients with type 1 diabetes (2012) (37)
Increased risk of malignant lymphoma indicated by elevated Epstein-Barr virus antibodies—a prospective study (1993) (37)
Trends over time in the incidence of cervical neoplasia in comparison to trends over time in human papillomavirus infection. (2000) (37)
Isolation, partial characterization, and molecular cloning of a human colon adenocarcinoma cell-surface glycoprotein recognized by the C215 mouse monoclonal antibody. (1993) (37)
Prospective Study of HPV16 Viral Load and Risk of In Situ and Invasive Squamous Cervical Cancer (2012) (37)
Methods in Biobanking (2011) (36)
No serological evidence of association between prostate cancer and infection with herpes simplex virus type 2 or human herpesvirus type 8: a nested case-control study. (2005) (36)
Nationwide comprehensive human papillomavirus (HPV) genotyping of invasive cervical cancer (2018) (36)
Effectiveness of cervical screening after age 60 years according to screening history: Nationwide cohort study in Sweden (2017) (36)
Time for a European initiative for research to prevent cancer: A manifesto for Cancer Prevention Europe (CPE) (2018) (36)
Activation of maternal Epstein-Barr virus infection and risk of acute leukemia in the offspring. (2006) (36)
Cervical cytology biobanks as a resource for molecular epidemiology. (2011) (36)
Population‐based study of screening test performance indices of three human papillomavirus DNA tests (2007) (36)
Human papillomavirus type-specific risk of cervical cancer in a population with high human immunodeficiency virus prevalence: case-control study. (2011) (36)
Evaluation of cost-precision rations of different strategies for ELISA measurement of serum antibody levels. (2002) (35)
Validation of multiplexed human papillomavirus serology using pseudovirions bound to heparin-coated beads. (2010) (35)
Does human papillomavirus-negative condylomata exist? (2015) (35)
Efficacy of HPV-based screening for prevention of invasive cervical cancer : Follow-up of four European randomized controlled trials (2014) (35)
Type- and age-specific distribution of human papillomavirus in women attending cervical cancer screening in Finland (2013) (35)
Induction of bovine papillomavirus E2 gene expression and early region transcription by cell growth arrest: correlation with viral DNA amplification and evidence for differential promoter induction (1990) (34)
Male Circumcision and Serologically Determined Human Papillomavirus Infection in a Birth Cohort (2009) (34)
Can genital-tract human papillomavirus infection and cervical cancer be prevented with a vaccine? (2004) (34)
Risk of second cancers after the diagnosis of Merkel cell carcinoma in Scandinavia (2010) (34)
A Nested Case-Control Study of Intrauterine Exposure to Persistent Organochlorine Pollutants and the Risk of Hypospadias (2012) (34)
Structural analysis of the human papillomavirus type 16-E2 transactivator with antipeptide antibodies reveals a high mobility region linking the transactivation and the DNA-binding domains. (1991) (34)
Cervical cancer case–control audit: Results from routine evaluation of a nationwide cervical screening program (2019) (33)
Organization and quality of HPV vaccination programs in Europe. (2015) (33)
Molecular and serological studies of human papillomavirus among patients with anal epidermoid carcinoma (1993) (33)
Evaluation of HPV type‐replacement in unvaccinated and vaccinated adolescent females—Post‐hoc analysis of a community‐randomized clinical trial (II) (2018) (33)
Attack rates of human papillomavirus type 16 and cervical neoplasia in primiparous women and field trial designs for HPV16 vaccination (2000) (33)
Eradication of human papillomavirus and elimination of HPV-related diseases – scientific basis for global public health policies (2019) (33)
Diversity of human papillomaviruses in skin lesions. (2013) (33)
Deletion of a major neutralizing epitope of human papillomavirus type 16 virus-like particles. (2007) (32)
Characterization of two novel cutaneous human papillomaviruses, HPV93 and HPV96. (2007) (32)
The impact of a quadrivalent human papillomavirus (types 6, 11, 16, 18) virus‐like particle vaccine in European women aged 16 to 24 (2009) (32)
Herpes simplex virus and human papillomavirus in a population‐based case‐control study of cervical intraepithelial neoplasia grade II‐III (1998) (32)
A population-based study of cervical carcinoma and HPV infection in Latvia. (2004) (32)
Squamous Cell Carcinoma of the Penis: Premalignant Lesions (2000) (32)
Seroepidemiology as basis for design of a human papillomavirus vaccination program. (2008) (32)
Decline of HPV infections in Scandinavian cervical screening populations after introduction of HPV vaccination programs. (2018) (32)
No serological evidence for non-sexual spread of HPV16 (1994) (32)
Prospective study on the development of antibodies against human papillomavirus type 6 among patients with condyloma acuminata or new asymptomatic infection (1995) (32)
Antibodies against papillomavirus antigens in cervical secretions from condyloma patients (1993) (31)
Continuing global improvement in human papillomavirus DNA genotyping services: The 2013 and 2014 HPV LabNet international proficiency studies. (2018) (31)
The Valgent4 protocol: Robust analytical and clinical validation of 11 HPV assays with genotyping on cervical samples collected in SurePath medium. (2018) (31)
Serum antibodies to human papillomavirus (HPV) pseudovirions correlate with natural infection for 13 genital HPV types. (2013) (31)
HLA-A0201 and HLA-B7 binding peptides in the EBV-encoded EBNA-1, EBNA-2 and BZLF-1 proteins detected in the MHC class I stabilization assay. Low proportion of binding motifs for several HLA class I alleles in EBNA-1. (1995) (30)
A prospective seroepidemiological study of human herpesvirus-8 infection and the risk of multiple myeloma (2001) (30)
MICA gene polymorphism and the risk to develop cervical intraepithelial neoplasia. (1999) (30)
Down‐regulation of the EBV‐encoded membrane protein (LMP) in burkitt lymphomas (1987) (30)
Age-specific HPV type distribution in high-grade cervical disease in screened and unvaccinated women. (2019) (30)
Laboratory Diagnosis of Human Herpesvirus 8 Infection in Humans (2002) (30)
Performance of Commercial Reverse Line Blot Assays for Human Papillomavirus Genotyping (2012) (30)
Interactions Between High- and Low-Risk HPV Types Reduce the Risk of Squamous Cervical Cancer. (2015) (29)
Long-term Antibody Response to Human Papillomavirus Vaccines: Up to 12 Years of Follow-up in the Finnish Maternity Cohort (2018) (29)
Re: Have we resolved how to triage equivocal cervical cytology? (2004) (29)
Maternal human polyomavirus infection and risk of neuroblastoma in the child (2005) (29)
Ensuring quality in studies linking cancer registries and biobanks (2010) (29)
Immunoglobulin A, G, and M responses to L1 and L2 capsids of human papillomavirus types 6, 11, 16, 18, and 33 L1 after newly acquired infection. (1998) (29)
Detection of DNA viruses in prostate cancer (2016) (29)
H. pylori Seropositivity before Age 40 and Subsequent Risk of Stomach Cancer: A Glimpse of the True Relationship? (2011) (28)
Human serum antibodies to a major defined epitope of human herpesvirus 8 small viral capsid antigen. (1999) (28)
International collaborative proficiency study of Human Papillomavirus type 16 serology. (2012) (28)
Epidemiology of Kaposi's Sarcoma herpesvirus (HHV8) in Västerbotten county, Sweden (2006) (27)
Type-Specific Human Papillomavirus Biological Features: Validated Model-Based Estimates (2013) (27)
High-Throughput Monitoring of Human Papillomavirus Type Distribution (2012) (26)
Deep sequencing detects human papillomavirus (HPV) in cervical cancers negative for HPV by PCR (2020) (26)
Impact of HPV vaccination on cervical screening performance: a population-based cohort study (2020) (26)
Prospective study of Merkel cell polyomavirus and risk of Merkel cell carcinoma (2014) (26)
The Bcl‐xL inhibitor of apoptosis is preferentially expressed in cutaneous squamous cell carcinoma compared with that in keratoacanthoma (2009) (26)
Epstein-Barr virus nuclear antigen 1 linear epitopes that are reactive with immunoglobulin A (IgA) or IgG in sera from nasopharyngeal carcinoma patients or from healthy donors (1991) (26)
HPV-16 L1 genes with inactivated negative RNA elements induce potent immune responses. (2004) (26)
Nuclear DNA-binding proteins determined by the Epstein-Barr virus-related simian lymphotropic herpesviruses H. gorilla, H. pan, H. pongo and H. papio. (1987) (26)
Validation of a standardized extraction method for formalin-fixed paraffin-embedded tissue samples. (2016) (26)
Phylogenetically diverse TT virus viremia among pregnant women. (2012) (25)
Introduction of human papillomavirus (HPV) vaccination in Sweden. (2009) (25)
The disease associations of the antibody response against the Epstein-Barr virus transactivator protein ZEBRA can be separated into different epitopes. (1995) (25)
Human papillomavirus antibody responses among patients with incident cervical carcinoma (1997) (25)
Vaginal self-sampling without preservative for human papillomavirus testing shows good sensitivity. (2013) (24)
Maternal smoking during pregnancy and testicular cancer in the sons: a nested case-control study and a meta-analysis. (2009) (24)
Joint Nordic prospective study on human herpesvirus 8 and multiple myeloma risk (2005) (24)
Order of HPV/Chlamydia infections and cervical high‐grade precancer risk: A case‐cohort study (2013) (24)
The Swedish cervical cytology biobank: sample handling and storage process. (2013) (24)
Bereavement Is Associated with an Increased Risk of HPV Infection and Cervical Cancer: An Epidemiological Study in Sweden. (2016) (24)
Registry-based assessment of the status of cervical screening in Sweden (2016) (24)
Prospective study of genital human papillomaviruses and nonmelanoma skin cancer (2013) (24)
Cost‐effectiveness of primary cytology and HPV DNA cervical screening (2008) (24)
Comparative effectiveness study on human papillomavirus detection methods used in the cervical cancer screening programme (2014) (24)
Increasing participation in cervical screening by targeting long‐term nonattenders: Randomized health services study (2019) (24)
A population‐based case‐control study of human papillomavirus‐type‐16 seropositivity and incident high‐grade dysplasia of the uterine cervix (1996) (23)
Extension of the viral ecology in humans using viral profile hidden Markov models (2018) (23)
A population-based study of human papillomavirus deoxyribonucleic acid testing for predicting cervical intraepithelial neoplasia. (1998) (23)
Correction: The Influence of Hormonal Factors on the Risk of Developing Cervical Cancer and Pre-Cancer: Results from the EPIC Cohort (2016) (23)
Low levels of serum vitamins A and E in blood and subsequent risk for cervical cancer: interaction with HPV seropositivity. (1999) (23)
Maternal Epstein‐Barr virus and cytomegalovirus infections and risk of testicular cancer in the offspring: a nested case‐control study (2008) (23)
Serology of human papillomavirus (1995) (23)
Seropositivity to Multiple Sexually Transmitted Infections Is Not Common (2000) (23)
Levels of immunoglobulin G antibodies against defined epitopes of the L1 and L2 capsid proteins of human papillomavirus type 6 are elevated in men with a history of condylomata acuminata (1992) (23)
Mapping of human serum-reactive epitopes in virus-like particles of human papillomavirus types 16 and 11. (2003) (23)
Different Challenges in Eliminating HPV16 Compared to Other Types: A Modeling Study (2017) (22)
Infection with Parvovirus B19 and Herpes viruses in early pregnancy and risk of second trimester miscarriage or very preterm birth. (2008) (22)
Scanning the structure and antigenicity of HPV-16 E6 and E7 oncoproteins using antipeptide antibodies. (1994) (22)
Malignant epithelial tumours (2006) (22)
Prevention of human papillomavirus-associated cancers. (2015) (22)
Patterns of Human Papillomavirus Types in Multiple Infections: An Analysis in Women and Men of the High Throughput Human Papillomavirus Monitoring Study (2013) (22)
Multianalyte serology in home-sampled blood enables an unbiased assessment of the immune response against SARS-CoV-2 (2021) (21)
Serological responses to papillomavirus group-specific antigens in women with neoplasia of the cervix uteri (1990) (21)
HPV‐mRNA and HPV‐DNA detection in samples taken up to seven years before severe dysplasia of cervix uteri (2018) (21)
Vaccination With Moderate Coverage Eradicates Oncogenic Human Papillomaviruses If a Gender-Neutral Strategy Is Applied (2020) (21)
Characterization of the complete genomes of Camelus dromedarius papillomavirus types 1 and 2. (2011) (21)
Occurrence of human papillomavirus (HPV) type replacement by sexual risk‐taking behaviour group: Post‐hoc analysis of a community randomized clinical trial up to 9 years after vaccination (IV) (2019) (21)
Randomised healthcare policy evaluation of organised primary human papillomavirus screening of women aged 56–60 (2017) (21)
Evaluation of 11 SARS-CoV-2 antibody tests by using samples from patients with defined IgG antibody titers (2021) (21)
Risk of high-grade lesions after atypical glandular cells in cervical screening: a population-based cohort study (2017) (20)
Upscaling human papillomavirus vaccination in high-income countries: impact assessment based on transmission model (2014) (20)
Human Papillomavirus Antibody Reference Reagents for Use in Postvaccination Surveillance Serology (2012) (20)
High-grade cervical intraepithelial neoplasia in human papillomavirus self-sampling of screening non-attenders (2017) (20)
Variable loss of antibody potency against SARS-CoV-2 B.1.1.529 (Omicron) (2021) (20)
Systematic evaluation of SARS‐CoV‐2 antigens enables a highly specific and sensitive multiplex serological COVID‐19 assay (2021) (20)
Preventive human papillomavirus vaccination (2002) (20)
Benefits of catch‐up in vaccination against human papillomavirus in medium‐ and low‐income countries (2013) (20)
Cellular and humoral immune responses to synthetic peptides deduced from the amino‐acid sequences of Epstein‐Barr virus‐encoded proteins in EBV‐transformed cells (1987) (20)
Genotyping of human papillomavirus in triaging of low-grade cervical cytology. (2011) (20)
Predominance of serum antibodies to synthetic peptide stemming from HPV 18 open reading frame E2 in cervical adenocarcinoma. (1992) (19)
Viruses in cancers among the immunosuppressed (2017) (19)
The interface of population-based cancer registries and biobanks in etiological and clinical research – current and future perspectives (2010) (19)
Randomized healthservices study of human papillomavirus‐based management of low‐grade cytological abnormalities (2011) (19)
Invitation strategies and coverage in the population-based cancer screening programmes in the European Union (2019) (19)
Cervical screening and risk of adenosquamous and rare histological types of invasive cervical carcinoma: population based nested case-control study (2019) (19)
Sound implementation of human papillomavirus vaccination as a community-randomized trial (2008) (19)
The Epstein‐Barr virus determined nuclear antigen is composed of at least three different anitgens (1986) (18)
Follow‐up of women with cervical cytological abnormalities showing atypical squamous cells of undetermined significance or low‐grade squamous intraepithelial lesion: a nationwide cohort study (2017) (18)
Long‐term HPV type‐specific risks for ASCUS and LSIL: A 14‐year follow‐up of a randomized primary HPV screening trial (2015) (18)
Cutaneous Human Papillomaviruses and Squamous Cell Carcinoma of the Skin: Nested Case–Control Study (2016) (18)
No Risk of Maternal EBV Infection for Childhood Leukemia (2009) (18)
Chlamydia trachomatis Strain Types Have Diversified Regionally and Globally with Evidence for Recombination across Geographic Divides (2017) (18)
Severe Acute Respiratory Syndrome Coronavirus 2 RNA in Serum as Predictor of Severe Outcome in Coronavirus Disease 2019: A Retrospective Cohort Study (2020) (17)
Laboratory audit as part of the quality assessment of a primary HPV-screening program. (2016) (17)
Disappearance of antibodies to HPV 16 E7 after treatment for cervical cancer (1993) (17)
Purification and characterization of the epstein‐barr virus nuclear antigen 2 using monoclonal antipeptide antibodies (1988) (17)
Human papillomavirus subtypes are not uncommon. (2007) (17)
Moderate variation of the oncogenic potential among high‐risk human papillomavirus types in gynecologic patients with cervical abnormalities (2003) (16)
Patients would benefit from simplified ethical review and consent procedure. (2013) (16)
Expressed Prostate Secretions in the Study of Human Papillomavirus Epidemiology in the Male (2013) (16)
Heparin-based ELISA reduces background reactivity in virus-like particle-based papillomavirus serology. (2005) (16)
Cutaneous human papillomavirus 88: Remarkable differences in viral load (2008) (16)
Duration of SARS-CoV-2 viremia and its correlation to mortality and inflammatory parameters in patients hospitalized for COVID-19: a cohort study (2021) (16)
Biobanks collected for routine healthcare purposes: build-up and use for epidemiologic research. (2011) (16)
Metagenomic sequencing of expressed prostate secretions (2014) (16)
Cervical cancer screening in Sweden 2014-2016 (2018) (16)
The Janus Serum Bank-From sample collection to cancer research (2009) (16)
Roadmap for a precision-medicine initiative in the Nordic region (2019) (16)
Poor antibody response against human papillomavirus in adult-onset laryngeal papillomatosis. (2001) (15)
Cervical cytology biobanking in Europe. (2010) (15)
Salivary sIgA response in HIV-1 infection. (1999) (15)
Methods for screening and diagnosis (2007) (15)
A novel human in vitro papillomavirus type 16 positive tonsil cancer cell line with high sensitivity to radiation and cisplatin (2019) (15)
ViraPipe: scalable parallel pipeline for viral metagenome analysis from next generation sequencing reads (2017) (14)
The WID-BC-index identifies women with primary poor prognostic breast cancer based on DNA methylation in cervical samples (2022) (14)
Pre-vaccination seroprevalence of 15 human papillomavirus (HPV) types among women in the population-based Slovenian cervical screening program. (2013) (14)
Risk stratification in cervical cancer screening by complete screening history: Applying bioinformatics to a general screening population (2017) (14)
A prospective study of antibody responses to defined epitopes of human papillomavirus (HPV) type 16 in relationship to genital and anorectal presence of HPV DNA. (1994) (14)
Primary screening for human papillomavirus infection. (2001) (13)
HPV-16 transmission (1995) (13)
Colposcopic and histopathologic evaluation of women with HPV persistence exiting an organized screening program. (2020) (13)
Serum p53 accumulation and altered antibody responses to Epstein‐Barr virus proteins precede diagnosis of haemopoietic malignancies of lymphoid origin (1996) (13)
Seroprevalences of Antibodies to 11 Human Papillomavirus (HPV) Types Mark Cumulative HPV Exposure (2018) (13)
Evaluation of serum antibody response to a newly identified B-cell epitope in the minor nucleocapsid protein L2 of human papillomavirus type 16. (1993) (13)
A translational multiplex serology approach to profile the prevalence of anti-SARS-CoV-2 antibodies in home-sampled blood (2020) (13)
De novo sequence assembly requires bioinformatic checking of chimeric sequences (2020) (13)
Transcription of human papillomavirus oncogenes in head and neck squamous cell carcinomas. (2020) (12)
Risk of invasive cervical cancer in relation to management of abnormal Pap smear results. (2009) (12)
Clustering of Seropositivities for Sexually Transmitted Infections (2002) (12)
Determinants of Human Papillomavirus Vaccine Uptake by Adult Women Attending Cervical Cancer Screening in 9 European Countries. (2020) (12)
Sequencing detects human papillomavirus in some apparently HPV-negative invasive cervical cancers. (2019) (12)
A seroepidemiologic study of HPV infection and incident cervical squamous intraepithelial lesions. (1994) (12)
No detection of SV40 DNA in mesothelioma tissues from a high incidence area in Sweden. (2007) (12)
Viremia during pregnancy and risk of childhood leukemia and lymphomas in the offspring: Nested case–control study (2016) (12)
Screening for nasopharyngeal carcinoma with an ELISA using the Epstein-Barr virus nuclear antigen, EBNA 1: a complementary test to the IgA/VCA immunofluorescence assay. (1993) (12)
Long‐term follow‐up of human papillomavirus type replacement among young pregnant Finnish females before and after a community‐randomised HPV vaccination trial with moderate coverage (2020) (11)
Seroepidemiology of human papillomavirus type 73: A sexually transmitted low‐risk virus (2000) (11)
Cancer Registry follow‐up for 17 million person‐years of a nationwide maternity cohort (2017) (11)
Serum antibody responses against human papillomavirus in relation to tumor characteristics, response to treatment, and survival in carcinoma of the uterine cervix (1995) (11)
Differences in risk for SARS-CoV-2 infection among healthcare workers (2021) (11)
Risk of SARS-CoV-2 exposure among hospital healthcare workers in relation to patient contact and type of care (2021) (11)
Enzyme immunoassay detection of induction of MHC class I expression by synthetic peptides from the E6 and E7 regions of human papillomavirus type 16. (1994) (11)
Human papillomavirus genotype distribution and socio-behavioural characteristics in women with cervical pre-cancer and cancer at the start of a human papillomavirus vaccination programme: the CIN3+ plus study (2019) (11)
Absence of epstein–barr and cytomegalovirus infection in neuroblastoma cells by standard detection methodologies (2013) (11)
How many Human Papillomavirus types do we need to screen for? (2020) (11)
Decline of the new Swedish variant of Chlamydia trachomatis after introduction of appropriate testing (2012) (11)
Antibodies against human papillomavirus type 6 capsids are elevated in men with previous condylomas (1997) (11)
Role of human papillomavirus (HPV) vaccination on HPV infection and recurrence of HPV related disease after local surgical treatment: systematic review and meta-analysis (2022) (10)
Are human papillomavirus DNA prevalences providing high-flying estimates of infection? An international survey of HPV detection on environmental surfaces (2013) (10)
Molecular size variation of EBNA is determined by the EB viral genome. (1984) (10)
Genome-wide transcriptome profiling of ex-vivo precision-cut slices from human pancreatic ductal adenocarcinoma (2020) (10)
Erratum: The influence of hormonal factors on the risk of developing cervical cancer and pre-cancer: Results from the EPIC cohort (PLoS ONE (2016) 11:1 (e0147029) DOI:10.1371/journal.pone.0147029) (2016) (10)
A summary of the 25th International Papillomavirus Conference 2009: vaccines, screening, epidemiology and therapeutics. (2010) (10)
The Launch of an International Animal Papillomavirus Reference Center (2019) (10)
A basis for translational cancer research on aetiology, pathogenesis and prognosis: Guideline for standardised and population-based linkages of biobanks to cancer registries. (2015) (10)
[Cervical cancer has increased in Sweden in women who had a normal cell sample]. (2018) (10)
Suppressive antiretroviral therapy associates with effective treatment of high-grade cervical intraepithelial neoplasia (2018) (10)
Primary induction of human cytotoxic lymphocytes against a synthetic peptide of the human immunodeficiency virus type 1 protease. (1997) (10)
Human papillomavirus types in cervical dysplasia among young HPV‐vaccinated women: Population‐based nested case–control study (2019) (10)
A dose-reduction HPV vaccine immunobridging trial of two HPV vaccines among adolescent girls in Tanzania (the DoRIS trial) – Study protocol for a randomised controlled trial (2021) (10)
Immunobiology of papillomavirus. Prospects for vaccination (1992) (10)
Sustained Cross-Reactive Antibody Responses After Human Papillomavirus Vaccinations: Up To 12 Years Follow-Up In The Finnish Maternity Cohort. (2020) (10)
Why follow‐back studies should be interpreted cautiously: The case of an HPV‐negative cervical lesion (2016) (10)
NordScreen - An Interactive Tool for Presenting Cervical Cancer Screening Indicators in the Nordic Countries (2018) (10)
Human papillomavirus genotype-specific risks for cervical intraepithelial lesions (2020) (10)
Evidence for at least two distinct groups of humoral immune reactions to papillomavirus antigens in women with squamous intraepithelial lesions. (1997) (10)
Risk of invasive cervical cancer in relation to clinical investigation and treatment after abnormal cytology: A population‐based case–control study (2011) (10)
Human Papillomavirus Infection Determines Prognosis in Cervical Cancer (2022) (10)
Pseudovirion-binding and neutralizing antibodies to cutaneous human papillomaviruses (HPV) correlated with the presence of HPV DNA in skin. (2013) (9)
Corrigendum: Detection of DNA viruses in prostate cancer (2016) (9)
Increase of cervical cancer incidence in Sweden in relation to screening history: population cohort study (2020) (9)
A systematic review of convalescent plasma treatment for COVID19 (2020) (9)
Human papillomavirus types in cervical high‐grade lesions or cancer among Nordic women—Potential for prevention (2019) (9)
Toward "serolomics": papillomavirus serology is taking a technologic lead in high-throughput multiplexed antibody analysis. (2005) (9)
Association of Short-term Air Pollution Exposure With SARS-CoV-2 Infection Among Young Adults in Sweden (2022) (9)
Lack of Significant Effects of Chlamydia trachomatis Infection on Cervical Adenocarcinoma Risk: Nested Case-Control Study (2016) (9)
Epstein-Barr virus (EBV) antigen-specific leukocyte migration inhibition (LMI) in infectious mononucleosis (IM). I. Kinetics and response to a membrane protein on EBV-transformed cells. (1986) (8)
Antibodies to SARS-CoV-2 and risk of past or future sick leave (2021) (8)
High amounts of SARS-CoV-2 precede sickness among asymptomatic healthcare workers (2021) (8)
The Epstein-Barr virus determined nuclear antigen is composed of at least three different antigens. (1986) (8)
Differences in transcriptional activity of cutaneous human papillomaviruses. (2008) (8)
HPV Types in Cervical Precancer by HIV Status and Birth Region: A Population-Based Register Study (2020) (8)
Bioinformatics for Viral Metagenomics (2013) (8)
Differing Age-Specific Cervical Cancer Incidence Between Different Types of Human Papillomavirus: Implications for Predicting the Impact of Elimination Programs (2020) (8)
Clinical validation of full genotyping CLART® HPV4S assay on SurePath and ThinPrep collected screening samples according to the international guidelines for human papillomavirus test requirements for cervical screening (2020) (8)
Early detection and prevention (2019) (8)
Human papillomavirus type 16 genomic variation in women with subsequent in situ or invasive cervical cancer: prospective population-based study (2018) (8)
Comparing one dose of HPV vaccine in girls aged 9–14 years in Tanzania (DoRIS) with one dose of HPV vaccine in historical cohorts: an immunobridging analysis of a randomised controlled trial (2022) (8)
[Condyloma typing important for follow up of HPV vaccination. A condyloma reporting project]. (2008) (7)
Human Papillomavirus (HPV) Prevalence in Male Adolescents 4 Years After HPV-16/18 Vaccination (2017) (7)
Antibodies against Kaposi sarcoma-associated herpes virus (KSHV) complement control protein (KCP) in infected individuals. (2007) (7)
Determinants of the presence of human papillomaviruses in the anal canal of Russian men (2018) (7)
Minor Cytological Abnormalities and up to 7-Year Risk for Subsequent High-Grade Lesions by HPV Type (2015) (7)
Cervical Cytology Biobanking in Europe (2010) (7)
Distribution of HPV Genotypes Differs Depending on Behavioural Factors among Young Women (2021) (7)
Serological responses to human papillomavirus type 16 antigens in women before and after renal transplantation (1993) (7)
Interactive effect of genetic susceptibility with height, body mass index, and hormone replacement therapy on the risk of breast cancer (2012) (7)
The 2019 HPV Labnet international proficiency study: Need of global Human Papillomavirus Proficiency Testing. (2021) (7)
Mutations in human papillomavirus type 16 L1 hypervariable surface-exposed loops affect L2 binding and DNA encapsidation. (2013) (6)
The process of moving from a regionally based cervical cytology biobank to a national infrastructure. (2015) (6)
A complex intervention for workflow enhancement at the Swedish cervical cytology biobank. (2014) (6)
International Quality Assurance of Human Papillomavirus Testing (2008) (6)
Chlamydia trachomatis infection is a risk factor for cervical cancer (2000) (6)
Seroconversion to islet autoantibodies between early pregnancy and delivery in non-diabetic mothers. (2011) (6)
Effect of naturally acquired type-specific serum antibodies against human papillomavirus type 16 infection. (2017) (6)
Viruses in case series of tumors: Consistent presence in different cancers in the same subject (2017) (6)
Regular Disappearance of the Human Papillomavirus Genome After Conization of Cervical Dysplasia by Carbon Dioxide Laser (2001) (6)
Strengthening prevention programs to eliminate cervical cancer in the Nordic countries (2008) (6)
Characterization of two novel cutaneous human papillomaviruses , HPV 93 and HPV 96 (2007) (6)
Estimating total excess mortality during a COVID-19 outbreak in Stockholm, Sweden (2020) (6)
A Simple Cervicovaginal Epigenetic Test for Screening and Rapid Triage of Women With Suspected Endometrial Cancer: Validation in Several Cohort and Case/Control Sets (2022) (6)
Prospects for accelerated elimination of cervical cancer. (2021) (6)
Can cervical cancer screening programs be improved by incorporating screening for human papillomavirus infection (1998) (6)
HPV transcription in skin tumors (2019) (6)
Human papillomavirus infection as a risk factor for anal and perianal skin cancer in a prospective study (2004) (6)
Elimination of HPV-associated oropharyngeal cancers in Nordic countries. (2021) (6)
Human papillomavirus vaccine efficacy against invasive, HPV-positive cancers: population-based follow-up of a cluster-randomised trial (2021) (6)
Prevalence of antibodies against Kaposi's sarcoma associated herpes virus (KSHV) complement inhibitory protein (KCP) in KSHV-related diseases and their correlation with clinical parameters. (2011) (5)
The HPV16 genome is stable in women who progress to in situ or invasive cervical cancer: a prospective population-based study. (2019) (5)
No evidence of HPV in epidemic and endemic Kaposi's sarcoma. (1993) (5)
Transcription of human papillomaviruses in nonmelanoma skin cancers of the immunosuppressed (2021) (5)
Performance Indicators in Breast Cancer Screening in the European Union: A Comparison Across Countries of Screen Positivity and Detection Rates. (2020) (5)
Fewer than three doses of HPV vaccine. (2015) (5)
The Antibody Response to Human Papillomavirus (1991) (5)
Baseline findings and safety of infrequent vs. frequent screening of human papillomavirus vaccinated women (2019) (5)
Sourcing of the WHO human papillomavirus type 18 international standards for HPV antibody levels. (2016) (5)
HPV-based screening for prevention of invasive cervical cancer – Authors' reply (2014) (5)
False-positive prostate cancer markers in a man with symptomatic urethral Chlamydia trachomatis infection (2013) (5)
Detection of adeno-associated virus type 2 genome in cervical carcinoma (2006) (5)
Assessing the risk of cervical neoplasia in the post‐HPV vaccination era (2022) (4)
Are twenty human papillomavirus types causing cervical cancer? (2014) (4)
Organized primary human papillomavirus–based cervical screening: A randomized healthcare policy trial (2021) (4)
Seropositivity to Multiple Anogenital Human Papillomavirus (HPV) Types Is Associated With Current Anogenital HPV Infection, Abnormal Cytology, and Seropositivity for Nongenital HPVs (2018) (4)
Cervical Cancer Screening by Human Papillomavirus Testing Followed by Cytology Triage (2017) (4)
Antibodies in human sera against the Epstein-Barr virus encoded latent membrane protein (LMP). (1988) (4)
Exposure to polychlorinated compounds and cryptorchidism; A nested case-control study (2020) (4)
Antibody responses to defined epitopes in the Epstein-Barr virus BZLF1-encoded transactivator protein among human immunodeficiency virus-infected patients (1996) (4)
Human papillomavirus seroprevalence in pregnant women following gender-neutral and girls-only vaccination programs in Finland: A cross-sectional cohort analysis following a cluster randomized trial (2021) (4)
Risk for SARS-CoV-2 infection in healthcare workers outside hospitals: A real-life immuno-virological study during the first wave of the COVID-19 epidemic (2021) (4)
Comparison of DNA and RNA sequencing of total nucleic acids from human cervix for metagenomics (2021) (4)
Immunogenicity and safety of one-dose human papillomavirus vaccine compared with two or three doses in Tanzanian girls (DoRIS): an open-label, randomised, non-inferiority trial (2022) (4)
International Journal of Cancer: Editorial (2009) (4)
Human Papillomavirus Serology Among Women Living With HIV: Type-Specific Seroprevalence, Seroconversion, and Risk of Cervical Reinfection (2018) (4)
[The new biobank law accepted: a unique chance of improvement]. (2002) (4)
Evaluation of human papillomavirus DNA detection in samples obtained for routine Chlamydia trachomatis screening. (2015) (4)
Tumor Necrosis Factor a-11 and DR 15-DQ 6 ( B * 0602 ) Haplotype Increase the Risk for Cervical Intraepithelial Neoplasia in Human Papillomavirus 16 Seropositive Women in Northern Sweden 1 (2000) (4)
A two-site enzyme immunoassay for quantitation of human papillomavirus type 16 particles. (1995) (3)
Probabilistic approaches for classifying highly variable anti-SARS-CoV-2 antibody responses (2020) (3)
Misclassifications in human papillomavirus databases. (2021) (3)
EUROCOURSE: towards optimisation of the use of cancer registries for scientific excellence in cancer research in Europe: an FP7 ERA-net project (2009) (3)
[The survey of Danish biobanks suggests a "drop-out" registry]. (2002) (3)
The WID-CIN test identifies women with, and at risk of, cervical intraepithelial neoplasia grade 3 and invasive cervical cancer (2022) (3)
Drug-induced tumor-specific cytotoxicity in a whole tissue ex vivo model of human pancreatic ductal adenocarcinoma (2022) (3)
SARS‐CoV‐2 infections amongst personnel providing home care services for older persons in Stockholm, Sweden (2021) (3)
Estimating effectiveness of HPV vaccination against HPV infection from post-vaccination data in the absence of baseline data. (2018) (3)
Probabilistic classification of anti‐SARS‐CoV‐2 antibody responses improves seroprevalence estimates (2022) (3)
Key issues that need to be considered while revising the current annex of the European Council Recommendation (2003) on cancer screening (2020) (3)
Pseudovirion-binding and neutralizing antibodies to cutaneous Human Papillomaviruses correlated to presence of HPV DNA in skin. (2013) (3)
Human exposome assessment platform (2021) (3)
Antibodies to SARS-CoV-2 and risk of future sickness (2020) (3)
Longitudinal biobanks-based study on the joint effects of infections, nutrition and hormones on risk of prostate cancer (2016) (3)
Validity of maternal genotypes in DNA from archival pregnancy serum samples. (2009) (3)
Annika with Kaposi ' s Sarcoma Immunodeficiency Virus-Infected Patients Peripheral Blood of Human Viral Load of Human Herpesvirus 8 in (2001) (2)
Metabolism of 25‐hydroxyvitamin D3 may explain the u‐shaped risk curve for prostate cancer (2004) (2)
Epstein-Barr virus (EBV) antigen-specific leukocyte migration inhibition in infectious mononucleosis. II. Kinetics of sensitization against five EBV-encoded nuclear proteins and the latent membrane protein. (1989) (2)
The 2011 HPV LabNet International Proficiency Study (2013) (2)
[Cervix cancer screening can be cost-effective. Combination of vaginal smears and the HPV test should be even more beneficial]. (2005) (2)
Severe features during outbreak but low mortality observed immediately before and after a March–May 2020 COVID-19 outbreak in Stockholm, Sweden (2021) (2)
A prospective study of the correlation between prediagnostic human papillomavirus seropositivity and HPV DNA presence in subsequently occurring cervical cancers (2003) (2)
HPV‐Positive Status Is an Independent Factor Associated With Sinonasal Inverted Papilloma Recurrence (2021) (2)
Merkel Cell Polyomavirus: Epidemiology and Clinical Features of Related Cancer (2014) (2)
Prophylactic vaccination against human papillomaviruses to prevent cervical cancer and its precursors. (2011) (2)
IgG Antibodies to Human Papillomavirus Type 16 and Serum Retinol May Jointly Protect Against Cervical Neoplasia (1994) (2)
Characterization of humoral immune responses against p16 in HPV-associated and non HPV-associated disease (2008) (2)
[Sexuality and STD infections among teenage girls. "Unprotected sex" is common in spite of sufficient knowledge about the risks]. (1997) (2)
The WID‐EC test for the detection and risk prediction of endometrial cancer (2022) (2)
Antibody responses to SARS-CoV-2 train machine learning to assign likelihood of past infection during virus emergence in Sweden (2020) (2)
Corrigendum to “Vaginal self-sampling without preservative for human papillomavirus testing shows good sensitivity” [J. Clin. Virol. 56 (2013) 52–56] (2013) (2)
Human papillomavirus load and genotype analysis improves the prediction of invasive cervical cancer (2021) (2)
Linear epitopes of the replication-activator protein of Epstein-Barr virus recognised by specific serum IgG in nasopharyngeal carcinoma (1995) (2)
IPVS policy statement on HPV nucleic acid testing guidance for those utilising/considering HPV as primary precancer screening: Quality assurance and quality control issues. (2022) (2)
Audit of laboratory sensitivity of human papillomavirus and cytology testing in a cervical screening program (2021) (2)
Prostate Cancer Risk and Serologic Evidence of Human Papilloma Virus Infection (2003) (2)
Comparable strategies needed to evaluate human papillomavirus vaccine efficiency across Europe. (2006) (2)
Nonvaccine human papillomavirus genotype common in women with HIV failing cervical precancer treatment (2021) (2)
Validation of the cobas 6800 human papillomavirus test in primary cervical screening (2021) (2)
Screening for high amounts of SARS-CoV-2 identifies pre-symptomatic subjects among healthy healthcare workers (2020) (2)
SARS-CoV-2 infections among personnel providing home care services for the elderly in Stockholm, Sweden (2020) (2)
A Population-Based Study of Human Papillomavirus Deoxyribonucleic Acid Testing for Predicting Cervical Intraepithelial Neoplasia (1999) (2)
Viremia preceding multiple sclerosis: Two nested case-control studies. (2018) (2)
Epstein-Barr virus gene expression during primary B-lymphocyte infection, in transformed and Burkitt lymphoma-derived cell lines. (1986) (2)
Human papillomavirus genotype and prognosis of invasive cervical cancer: A nationwide cohort study. (2019) (2)
Potential SARS-CoV-2 infectiousness among asymptomatic healthcare workers (2021) (2)
Machine Learning for detection of viral sequences in human metagenomic datasets (2018) (2)
Human Papillomavirus (HPV) seroprevalence, cervical HPV prevalence, genotype distribution and cytological lesions in solid organ transplant recipients and immunocompetent women in Sao Paulo, Brazil (2022) (2)
Human papillomavirus seroprevalence and seroconversion among men living with HIV: Cohort study in South Africa. (2020) (1)
Editorial (2009) (1)
44. Detection of the human papillomavirus infection (HPV) on the internationally used environmental surfaces: ready for a ‘take-off’? (2013) (1)
Screening for Cervical Cancer (2012) (1)
Cervical cancer screening improvements with self- sampling during the COVID-19 pandemic (2022) (1)
Erratum: Human papillomavirus infection as a risk factor for anal and perianal skin cancer in a prospective study (British Journal of Cancer (2002) 87 (61-64) doi: 10.1038/sj.bjc.6600350) (2004) (1)
The Use of Antibodies against Synthetic Peptides for Studying the EBV Nuclear Antigen (1985) (1)
Stratifying Cervical Cancer Risk with Registry Data (2018) (1)
Comparison of cytology and human papillomavirus-based primary testing in cervical screening programs in the Nordic countries (2021) (1)
43. Anal human papillomavirus prevalence in HIV-negative and HIV-infected Russian men who have sex with women (2013) (1)
HPV Vaccination and the Risk of Invasive Cervical Cancer (2021) (1)
Prevalence of antibodies against Kaposi's sarcoma associated herpes virus (KSHV) complement inhibitory protein (KCP) in KSHV-related diseases and their correlation with clinical parameters (2011) (1)
Response to the author: invitation to cancer screening: putting the car before the horse? (2019) (1)
SARS-CoV-2 Infections Among Healthcare Workers Outside Hospitals (2021) (1)
Improving human papillomavirus (HPV) testing in the cervical cancer elimination era: The 2021 HPV LabNet international proficiency study (2022) (1)
Nationwide Rereview of Normal Cervical Cytologies before High-Grade Cervical Lesions or before Invasive Cervical Cancer (2021) (1)
Author's reply to: Human papillomavirus type 197 is not associated with skin tumors (2019) (1)
FAST TRACK EUROGIN 2008 roadmap on cervical cancer prevention (2009) (1)
[Swedish consensus on cervix cancer vaccination. Vaccination programs for eradication of HPV16/18 should be initiated in elementary schools]. (2006) (1)
HPV type replacement in the post-vaccination era (2006) (1)
Genetic predisposition, parity, age at first childbirth and risk for breast cancer (2012) (1)
Serological Responses toPapillomavirus Group-Specific Antigens in WomenwithNeoplasia oftheCervix Uteri (1990) (1)
Atypical glandular cells and development of cervical cancer: Population‐based cohort study (2022) (1)
WHO HPV LabNet-Newsletter 05 WHO HPV LabNet World Health Organization ’ s Global Human Papillomavirus ( HPV ) Laboratory Network (2007) (1)
[How to handle biological material? New legislation concerning biobanks in Finland]. (2001) (1)
Cervical screening: ESGO-EFC position paper of the European Society of Gynaecologic Oncology (ESGO) and the European Federation of Colposcopy (EFC) (2020) (1)
Head-to-Head Comparison of Bi- and Nonavalent Human Papillomavirus Vaccine-Induced Antibody Responses (2022) (1)
Convalescent plasma for treatment of COVID-19: study protocol for an open randomised controlled trial in Sweden (2021) (1)
Rapid Communication Human papillomavirus subtypes are not uncommon (2007) (1)
Estimating COVID-19 contribution to total excess mortality (2020) (1)
Induction of Broadly Cross-neutralizing Antisera against Mucosal and Cutaneous Human Papillomayiruses (HPV) by HPV16L1-16L2 Virus-like Particles (RG1-VLP) (2010) (0)
Serum testosterone, sex hormone binding globulin and prostate cancer risk. A Nordic nested case-control study (2004) (0)
976 H. pylori Seropositivity Before Age 40 and Subsequent Risk of Stomach Cancer: A Glimpse of the True Relationship? (2009) (0)
Author's reply to: Implementation and organization of cancer screening in France (2018) (0)
Human Papillomavirus Types in Invasive Cervical Cancer in Relation to Cervical Screening (2022) (0)
Multiplex detection of human herpesviruses from archival specimens using MALDI-TOF mass spectrometry (2007) (0)
Contents Vol. 81, 2014 (2015) (0)
HPV-based screening for prevention of invasive cervical cancer Reply (2014) (0)
Viral infections and Cancer (2010) (0)
Chlamydia trachomatis and cervical squamous cell carcinoma (Letter, in reply) (2001) (0)
A pilot study of risk-stratified cervical cancer screening (2021) (0)
A NESTED CASE-CONTROL STUDY OF INTRAUTERINE EXPOSURE TO PERSISTENT ORGANOCHLORINE POLLUTANTS IN RELATION TO RISK OF HYPOSPADIA (2011) (0)
Human papillomavirus type 16 genomic variation in women with subsequent in situ or invasive cervical cancer: prospective population-based study (2018) (0)
Genome-wide transcriptome profiling of ex-vivo precision-cut slices from human pancreatic ductal adenocarcinoma (2020) (0)
Immunogenicity and Safety Results Comparing Single Dose Human Papillomavirus Vaccine with Two or Three Doses in Tanzanian Girls - the DoRIS Randomised Trial (2022) (0)
To the editor: Chlamydia trachomatis and cervical cancer (2001) (0)
HPV 16-Derived Synthetic Peptides with Ability to Upregulate MHC Class I Expression on RMA-S or T2 Cells, as Detected by Enzyme Immunoassay (1994) (0)
Professor Geo von Krogh (2010) (0)
Professor Geo von Krogh Obituary (2010) (0)
Both high and low level of vitamin D are associated with a higher prostate cancer risk. A prediagnostic study in stored sera (2004) (0)
Near full control of human papillomavirus vaccine types. (2015) (0)
Exploration of Patient-Derived Pancreatic Ductal Adenocarcinoma Ex Vivo Tissue for Treatment Response (2023) (0)
Current opinions on papillomaviruses (1994) (0)
Process for the human papillomavirus (HPV) detection for diagnostic use (1991) (0)
Prospective StudyofHPV16Viral LoadandRiskofInSituand Invasive Squamous Cervical Cancer (2013) (0)
Antibodies to the latent human papillomavirus proteins, diagnostic systems and diagnostic methods (1989) (0)
Maternal smoking during pregnancy, and testicular cancer in the offspring (2008) (0)
P3.002 Detection of Human Papillomavirus (HPV) Infection in Anal Samples in Russian Men Who Have Sex with Women (MSW) (2013) (0)
A novel human in vitro papillomavirus type 16 positive tonsil cancer cell line with high sensitivity to radiation and cisplatin (2019) (0)
Overtreatment rate after immediate local excision of suspected cervical intraepithelial neoplasia: A prospective cohort study. (2022) (0)
Human papillomavirus infection as a risk factor for anal and perianal skin cancer in a prospective study. (Corr. 2004;91(6):1226) (2002) (0)
Proceedings of the HPV vaccination workshop: vaccinating women against premature death. (2000) (0)
Some clear answers regarding transmission of genital human papillomavirus. (2019) (0)
Abstract II: No difference in JCV or BKV seroprevalence between colon cancer patients and controls (2005) (0)
Vaccinating women against premature death: summary of an International Workshop, Helsinki, Finland, 10.01.2000. (2001) (0)
Author's reply to: Cancer screening policy in Hungary (2018) (0)
[Evaluable implementation of HPV testing]. (2013) (0)
Human papillomavirus genotype distribution and socio-behavioural characteristics in women with cervical pre-cancer and cancer at the start of a human papillomavirus vaccination programme: the CIN3+ plus study (2019) (0)
Authors' reply. (2020) (0)
Creating personas for exposome research: the experience from the HEAP project (2023) (0)
Abstract I: Prevalence and stability of human serum antibodies to simian virus 40 VP1 virus-like particles (2005) (0)
Risk of invasive cervical cancer in relation to cytologic results in the screening history : a population‐based case‐control study (2011) (0)
Nationwide comprehensive human papillomavirus (HPV) genotyping of invasive cervical cancer (2018) (0)
Antibody to human papillomavirus latent protein, diagnostic system and its use (1989) (0)
NFKK meeting - Biobanks (2002) (0)
Evidence of Association between Prostate Cancer and Infection with Herpes Simplex Virus Type 2 or Human Herpesvirus Type 8 : A Nested Case-Control Study (2005) (0)
Polypeptides which react with antibodies against latent human papillomavirus proteins, antibodies reactive with polype (1989) (0)
leukoencephalopathy? for elevated risk of progressive multifocal treated with immunosuppression: can we screen JC viral loads in patients with Crohn's disease (2008) (0)
To the editor: Human papillomavirus infection as a risk factor for squamous cell carcinoma of the head and neck (2001) (0)
P1137 Human papillomavirus infection and risk of in situ and invasive cervical adenocarcinoma (2009) (0)
Decoding our environment: The European Human Exposome Network (2021) (0)
Evaluation of co-testing with cytology and human papillomavirus testing in cervical screening. (2022) (0)
Antibodies against latent proteins of human papillomavirus, diagnostic systems and methods. (1989) (0)
Comparison of Immune Responses after One Dose of HPV Vaccine in a Dose-Reduction HPV Vaccine Trial in Adolescent Girls in Tanzania to the Costa Rica Vaccine and India HPV Vaccine Trials (2022) (0)
O16.6 Pre-Vaccination Seroprevalence of 15 Human Papillomavirus (HPV) Types Among Slovenian Women Screened For Cervical Cancer (2013) (0)
237 Post-vaccination HPV surveillance (2009) (0)
Human papillomavirus self‐sampling with mRNA testing benefits routine screening (2022) (0)
Monoclonal antibodies against human papillomavirus E7 oncoprotein for diagnosis of cervical neoplasia and cancer (2012) (0)
WITHDRAWAL—Administrative Duplicate Publication: The essential role of prevention in reducing the cancer burden in Europe: a commentary from Cancer Prevention Europe (2019) (0)
Quality assurance in human papillomavirus testing for primary cervical screening (2023) (0)
Faculty Opinions recommendation of Impact of scaled up human papillomavirus vaccination and cervical screening and the potential for global elimination of cervical cancer in 181 countries, 2020-99: a modelling study. (2019) (0)
Population-Based Human Papillomavirus Serosurvey Reveals HPV16/18 Herd Effect But No Clear Type-Replacement in Unvaccinated Females 6 Years Post Gender-Neutral Vaccination in a Cluster Randomised Trial (2019) (0)
HPV seroprevalence and seroconversion among women living with HIV-1 : cohort study in South Africa. (2017) (0)
Clinical validation of full genotyping CLART® HPV4S assay on SurePath and ThinPrep collected screening samples according to the international guidelines for human papillomavirus test requirements for cervical screening (2020) (0)
P825 HPV seroprevalence and seroconversion among HIV-positive men: cohort study in south africa (2019) (0)
[Testing HPV vaccine is an ethical dilemma. Can we afford not to offer vaccination against an infection which is a cause of cancer?]. (2003) (0)
Is the elimination of cervical cancer now 3 times easier? One-dose vaccine efficacy has far-reaching implications (2022) (0)
HPV‐induced host epigenetic reprogramming is lost upon progression to high‐grade cervical intraepithelial neoplasia (2023) (0)
Roadmap for a precision-medicine initiative in the Nordic region (2019) (0)
Antigenic andImmunogenic Epitopes SharedbyHuman Papillomavirus Type16andBovine, Canine, and AvianPapillomaviruses (1991) (0)
Human Papillomavirus (HPV) 26 and HPV 88 replicate to extremely high levels in squamous cell carcinomas (SCC) of the nail unit in anHIV-immunosuppressed patient (2008) (0)
Upscaling human papillomavirus vaccination in high-income countries: impact assessment based on transmission model (2014) (0)
LBP-1.07 Ecology of Human papillomavirus (HPV) infections in the male, studied using Expressed Prostate Secretions (EPS) (2011) (0)
In Vivo and In Vitro Intragenomic Rearrangement of TT Viruses (cid:1) (2007) (0)
Impact of HPV vaccination on cervical screening performance: a population-based cohort study (2020) (0)
Extremely high viral loads of HPV26 and HPV88 in squamous cell carcinomas (SCC) of the nail unit in an HIV-immunosuppressed patient (2008) (0)
Shared environment and colorectal cancer: A Nordic pedigree registry‐based cohort study (2022) (0)
DNA methylation-based detection and prediction of cervical intraepithelial neoplasia grade 3 and invasive cervical cancer with the WID™-qCIN test (2022) (0)
Predicting past and future SARS-CoV-2-related sick leave using discrete time Markov modelling (2022) (0)
P2-164 Human papillomavirus, other sexually transmitted infections and risk of cervical cancer. A Nordic Joint Study (2011) (0)
[Experts: Good evidence for screening recommendations]. (2015) (0)
Chapter 5. Evaluation of durability of protection of HPV prophylactic vaccines (2014) (0)
Latent protein antibodies of human papillomavirus, diagnostic systems and procedures. (1989) (0)
Prevalence of Antibodies Against Defined HPV Epitopes Among Incident Cases of Cervical Neoplasia: Current Status and Concepts (1994) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With Joakim Dillner?

Joakim Dillner is affiliated with the following schools:

Aarhus University
Malmö University
Lund University
Karolinska Institute

Joakim Dillner's Academic­Influence.com Rankings

Why Is Joakim Dillner Influential?

Joakim Dillner's Published Works

Published Works

What Schools Are Affiliated With Joakim Dillner?

Joakim Dillner's AcademicInfluence.com Rankings